Free Trial
NASDAQ:CLLS

Cellectis Q2 2024 Earnings Report

Cellectis logo
$1.52 +0.01 (+0.99%)
As of 04/25/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cellectis EPS Results

Actual EPS
-$0.28
Consensus EPS
-$0.33
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

Cellectis Revenue Results

Actual Revenue
$9.50 million
Expected Revenue
$6.00 million
Beat/Miss
Beat by +$3.50 million
YoY Revenue Growth
N/A

Cellectis Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Tuesday, August 6, 2024
Conference Call Time
10:30AM ET

Upcoming Earnings

Cellectis' Q1 2025 earnings is scheduled for Monday, May 5, 2025

Earnings Documents

Cellectis Earnings Headlines

StockNews.com Upgrades Cellectis (NASDAQ:CLLS) to Buy
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
Barclays Sticks to Their Buy Rating for Cellectis SA (CLLS)
See More Cellectis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cellectis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cellectis and other key companies, straight to your email.

About Cellectis

Cellectis (NASDAQ:CLLS), a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

View Cellectis Profile

More Earnings Resources from MarketBeat